Financial Performance Q1 FY27

  • Revenue from operations increased approximately 9% year-on-year to ₹82 crores
  • Gross profit grew over 10% to ₹54 crores, with gross margins improving to 65%+
  • Operating EBITDA increased by around 21% to approximately ₹19 crores, with margins above 23% (240 bps expansion)
  • PAT grew by 22% to ₹13 crores, with margins improving by 176 bps to 16%
  • The company maintained strong operating cash generation supported by disciplined working capital management
  • Closing cash balance stood at ₹170 crores

Strategic Acquisition

  • Completed acquisition of 85% stake in Aequitas Healthcare for ₹20.8 crores
  • Aequitas provides immediate entry into the hospital segment with FY26 revenue of ₹53 crores
  • Acquisition brings 49 institutional medical representatives, access to over 1,000 hospitals, and relationships with 4,000 specialty doctors
  • Integration planning is underway with expected benefits to become progressively visible in coming quarters
  • Target: ₹100 crores business within 2.5 years and ₹10 crores EBITDA by year two post-integration
  • Aequitas focuses on corporate hospital chains (not government tenders) with products in ICU antibiotics, volume enhancers, injectables for perioperative usage, anesthesia, nutrition, pain relievers, and anti-acids

Capital Allocation & Shareholder Returns

  • Successfully completed ₹40 crores share buyback subscribed 3.67x at a 40% premium to then prevalent market price
  • Recouped almost 50% of the buyback payout within the quarter
  • ROCE improved by approximately 340 bps and ROE expanded by 250 bps
  • Board recommended dividend of 200% (including special dividend of 75%) in April '26, to be paid post shareholder approval at ensuing AGM
  • Over last four years (FY22-FY26): Generated over ₹250 crores operating cash, deployed ₹90+ crores for Yash Pharma acquisition, returned ₹40+ crores dividends and ₹40 crores buyback

Operational Highlights

  • Company grew 18.9% in Pharmarack data versus industry growth of 11.6% in the quarter
  • Shifting portfolio from acute therapies toward higher-value semi-chronic and specialty treatments
  • Power brand portfolio reflected growth of 19% versus market growth of 16%
  • Five brands rank #1 in respective molecules while 14 brands are among top five
  • Top performing brands: Maintane (₹46 crores MAT: ₹34 crores injections, ₹13 crores tablets), Indocap, Endoreg, Lycored
  • Implemented people-centric initiatives including MBA program for sales team and "Bahubali" incentive system
  • Rolled out company-wide lean and green productivity improvement program

Board Changes

  • Ms. Pallavi Dinodia Gupta stepped down citing personal commitments
  • Mr. Anil Kumar Matai joined as Independent Director bringing three decades of pharmaceutical and healthcare leadership experience

Growth Strategy

Four pillars of growth strategy:

1. Accelerating organic growth through portfolio shift to semi-chronic and specialty therapies

2. Brand building moving from product-centric to brand-centric approach

3. Productivity improvement through operational excellence

4. Value-accretive inorganic opportunities

Q&A Session Highlights

  • Management addressed variance between primary (9%) and secondary (18.9%) sales growth, attributing to statistical considerations and inventory buffers
  • Confirmed guidance to grow at 1.5x Indian pharma industry rate
  • Discussed Aequitas integration timeline and EBITDA improvement drivers including cross-selling Jagsonpal brands into hospital segment
  • Detailed working capital improvements driven by inventory control and disciplined collections
  • Explained lower gross margins in hospital business (Aequitas) compared to branded prescription business due to price sensitivity in corporate chains
  • Identified key growth brands: Indocap, Maintane, Endoreg, Pru, and Eukroma
  • Confirmed Pan India presence with top hospital chains including Max, Manipal, Vedanta, Cloudnine, Rainbow, and Aster DM